Niznik JD, Zhao X, He M, et al. - Among nonskilled residents of US Medicare–certified nursing homes, aged 65 years and older, with severe dementia, researchers investigated patient-, provider-, and system-level features related to acetylcholinesterase inhibitor (AChEI) discontinuation. The participants were taking AChEIs within the first 14 days of a Minimum Data Set evaluation in 2016 (n = 37,106). At 1 year of follow-up, the cumulative incidence of AChEI discontinuation was just under 30%. New admission, older age, difficulty being understood, aggressive behavior, poor appetite, weight loss, mechanically altered diet, limited prognosis designation, hospitalization in 90 days prior, and northeastern region were all identified as factors related to an increased probability of discontinuation. Memantine use, use of strong anticholinergics, polypharmacy, rurality, and primary care prescriber vs geriatric specialist were documented as factors related to reduced probability of discontinuation.